Anastrozole starts lowering estrogen levels within 24 hours of the first dose, reducing estradiol by roughly 70% in that first day alone. After two weeks of daily dosing, suppression reaches approximately 80%. But the full picture of “working” depends on what you’re measuring: the drug’s immediate biological effect, the time to reach stable levels in your body, or the longer timeline over which it delivers clinical benefits like reducing cancer recurrence.
How Quickly Estrogen Levels Drop
Anastrozole works by blocking the enzyme that converts other hormones into estrogen. In postmenopausal women, this enzyme is the primary source of estrogen production. Once you take your first 1 mg tablet, the drug begins shutting down that conversion almost immediately.
The FDA label puts specific numbers on this: a 70% reduction in estradiol within the first 24 hours, climbing to about 80% suppression by day 14. The drug has a long half-life of approximately 50 hours, meaning it clears slowly and builds up with daily dosing. It takes roughly 7 to 10 days of consecutive doses to reach steady-state levels, the point where the amount entering your system each day matches the amount being cleared.
After six months of treatment, data from Clinical Cancer Research shows that about 58% of women on anastrozole achieve 90% or greater estradiol suppression. Another 40% see reductions in the range of 0 to 89%. A small fraction, roughly 2%, don’t experience meaningful suppression at all. This variability matters because the degree of estrogen suppression appears linked to outcomes.
Why Body Weight Can Affect How Well It Works
One factor that influences anastrozole’s effectiveness is body mass index. Women with higher BMI tend to have more of the estrogen-producing enzyme in fatty tissue, which means there’s simply more estrogen production to overcome. At the same time, their anastrozole blood levels are actually about 25% higher than in women at a normal weight, likely because the drug is metabolized differently.
Despite those higher drug levels, women with excess weight also show signs of greater residual estrogenic activity. Their bodies are producing more estrogen to begin with, and the standard 1 mg dose may not fully compensate. Some researchers have suggested that dose adjustments based on body weight could improve outcomes, though this isn’t yet part of standard practice. If you have concerns about your weight and treatment effectiveness, this is worth discussing with your oncologist.
When Side Effects Typically Appear
Joint and muscle pain is the most common side effect that leads women to consider stopping treatment. The median onset is about 6 weeks after starting anastrozole, though symptoms can develop at any point during therapy. For women who do experience musculoskeletal symptoms, they tend to peak around the 6-month mark. This is also the point at which women who ultimately discontinue the drug are most likely to do so.
Hot flashes and fatigue often begin earlier, within the first few weeks, as estrogen levels drop. These side effects are a direct result of the drug doing what it’s designed to do. For many women, they stabilize or become more manageable over time, though they can persist throughout treatment.
The Standard Treatment Duration
For postmenopausal women with hormone receptor-positive early-stage breast cancer, five years of daily anastrozole is the current standard. This isn’t about how long the drug takes to “work” in a pharmacological sense. It’s about how long continued estrogen suppression reduces the risk of cancer returning. The drug is active in your body within hours, but its protective benefit accumulates over years of consistent use.
A randomized trial published in the Journal of Clinical Oncology (the AERAS trial) evaluated whether extending treatment to 10 years offered additional benefit beyond the standard five. The results inform ongoing conversations between patients and oncologists about whether longer treatment is worthwhile given the side effect burden.
Monitoring During Treatment
Because anastrozole suppresses estrogen so aggressively, it accelerates bone density loss. Most expert panels recommend a baseline bone density scan when you start treatment, with follow-up scans every one to two years. The American Society of Clinical Oncology recommends annual screening, while the National Comprehensive Cancer Network suggests at least every two years.
Your oncologist will also monitor your overall response to treatment through regular follow-ups, but there’s no routine blood test to check whether your estrogen is “low enough.” The drug is prescribed at a fixed 1 mg daily dose, and adjustments are uncommon. If you’re tolerating the medication and taking it consistently, the pharmacology is predictable enough that the standard dose reliably suppresses estrogen in most women within the first two weeks.